Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


Regulation of gene expression by progesterone in cancer cells: effects on cyclin D1, EGFR and VEGF.

Hernández-Hernández OT, Camacho-Arroyo I.

Mini Rev Med Chem. 2013 Apr 1;13(5):635-42. Review.


Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.

Hernández-Hernández OT, González-García TK, Camacho-Arroyo I.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):127-34. doi: 10.1016/j.jsbmb.2012.04.005. Epub 2012 Apr 21.


Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.

Giulianelli S, Vaqué JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA, Gutkind JS, Lanari C.

Cancer Res. 2012 May 1;72(9):2416-27. doi: 10.1158/0008-5472.CAN-11-3290. Epub 2012 Mar 6.


Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.

Dressing GE, Knutson TP, Schiewer MJ, Daniel AR, Hagan CR, Diep CH, Knudsen KE, Lange CA.

Mol Endocrinol. 2014 Apr;28(4):442-57. doi: 10.1210/me.2013-1196. Epub 2014 Feb 25.


p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.

Liang Y, Wu J, Stancel GM, Hyder SM.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. Epub 2005 Jan 28.


Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.

Neubauer H, Adam G, Seeger H, Mueck AO, Solomayer E, Wallwiener D, Cahill MA, Fehm T.

Climacteric. 2009 Jun;12(3):230-9. doi: 10.1080/13697130802635637.


Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.

Faivre EJ, Daniel AR, Hillard CJ, Lange CA.

Mol Endocrinol. 2008 Apr;22(4):823-37. doi: 10.1210/me.2007-0437. Epub 2008 Jan 17.


Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.

Subtil-Rodríguez A, Millán-Ariño L, Quiles I, Ballaré C, Beato M, Jordan A.

Mol Cell Biol. 2008 Jun;28(11):3830-49. doi: 10.1128/MCB.01217-07. Epub 2008 Mar 31.


EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Löhrs U.

Breast Cancer Res Treat. 2003 May;79(2):187-98.


The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression.

Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP.

Steroids. 2008 Oct;73(9-10):922-8. doi: 10.1016/j.steroids.2008.01.010. Epub 2008 Jan 19. Review.


Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.

Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB.

J Biol Chem. 2002 Feb 15;277(7):5209-18. Epub 2001 Nov 20.


Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression.

Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV.

Mol Cell Biol. 2010 Jun;30(12):3111-25. doi: 10.1128/MCB.01398-09. Epub 2010 Apr 19.


Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis.

Hadzisejdić I, Mustać E, Jonjić N, Petković M, Grahovac B.

Mod Pathol. 2010 Mar;23(3):392-403. doi: 10.1038/modpathol.2009.166. Epub 2010 Jan 8.


Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers.

Kariagina A, Xie J, Leipprandt JR, Haslam SZ.

Horm Cancer. 2010 Oct;1(5):229-44. doi: 10.1007/s12672-010-0048-0. Epub 2010 Nov 23.


G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.

Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M.

Cancer Res. 2007 Feb 15;67(4):1859-66.


Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV.

J Clin Oncol. 2005 Oct 20;23(30):7721-35. Review.


Supplemental Content

Support Center